{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T05:42:40Z","timestamp":1698730960884},"reference-count":13,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":187,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p>Carisbamate's effect (200 mg twice\u2010daily [study 1], 600 mg twice\u2010daily [study 2]) on warfarin's (25 mg single dose) pharmacokinetics and pharmacodynamics (international normalized ratio) was assessed during 2 open\u2010label studies in healthy participants. Coadministration of either carisbamate regimen produced small changes on the mean maximum plasma concentration (C<jats:sub>max<\/jats:sub>) and mean area under the plasma concentration\u2014time curve to the last measurable time point (AUC<jats:sub>last<\/jats:sub>) of (S)\u2010 and (R)\u2010warfarin, which are unlikely to be clinically significant. For (S)\u2010warfarin, the ratios (with carisbamate\/without carisbamate) of geometric means for C<jats:sub>max<\/jats:sub> were 105.44 (study 1) and 98.48 (study 2) and for AUC<jats:sub>last<\/jats:sub> were 109.33 (study 1) and 114.43 (study 2); the corresponding 90% confidence intervals were within the bioequivalence limits of 80% to 125%. Results were similar for (R)\u2010warfarin. Carisbamate at 600 mg (but not 200 mg) twice\u2010daily prolonged the elimination half\u2010life of (S)\u2010 and (R)\u2010warfarin by \u223c10 hours (25% and 32% increase, respectively). Prothrombin time was unaltered by either carisbamate dose. Adverse events with the highest incidence were dizziness (50%) and headache (50%) in study 1 and somnolence (56%) in study 2. Warfarin exposure and international normalized ratio were unaffected by coadministration of carisbamate 200 mg or 600 mg twice\u2010daily. Carisbamate was well tolerated.<\/jats:p>","DOI":"10.1177\/0091270011415412","type":"journal-article","created":{"date-parts":[[2011,10,20]],"date-time":"2011-10-20T03:32:42Z","timestamp":1319081562000},"page":"1420-1429","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Carisbamate on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Participants"],"prefix":"10.1002","volume":"52","author":[{"given":"Martha","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Zannikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allitia","family":"DiBernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Robert","family":"Brashear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Ariyawansa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000334751.89859.7f"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02960.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02318.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22872"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01326.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.011940"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.016"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00815.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01037.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106273242606"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0278"},{"key":"e_1_2_7_13_2","unstructured":"USFDA.Guidance for industry\u2010In vivo drug metabolism\/drug interaction studies\u2014study design data analysis and recommendations for dosing and labeling.1999. Assessed June 29 2011. Available fromhttp:www.fda.govdownloadsDrugsGuidanceComplianceRegulatoryInformationGuidancesUCM072119.pdf."},{"key":"e_1_2_7_14_2","unstructured":"GonzalezM ZannikosP TianH BrashearRH SellersE SetnikB Antiepileptic agent carisbamate does not interact with ethanol. Poster presented at: 37th annual meeting of the American College of Clinical Pharmacology (ACCP);September 1416 2008; Philadelphia PA."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270011415412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270011415412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T06:18:24Z","timestamp":1698646704000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270011415412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1177\/0091270011415412"],"URL":"https:\/\/doi.org\/10.1177\/0091270011415412","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}